Showing 105 of 105on this page. Filters & sort apply to loaded results; URL updates for sharing.105 of 105 on this page
FDA Approves Elranatamab for Multiple Myeloma
Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory ...
Elranatamab | Pfizer Oncology Development Website
Thuốc Elranatamab điều trị bệnh u tủy đa tái phát hoặc kháng trị
Elranatamab (ELREXFIO®) [Acthera]
Pivotal MagnetisMM-3 Trial Aims to Add Elranatamab in Multiple Myeloma ...
Elranatamab in Combination with Daratumumab for Patients with Relapsed ...
Safety and Efficacy of elranatamab in RRMM & Prior BCMA Therapies ...
(PDF) Elranatamab in relapsed or refractory multiple myeloma: the ...
Elranatamab Improves Survival in Phase 3 Trial for Relapsed/Refractory ...
Study Comparing Elranatamab and Lenalidomide with Daratumumab and ...
Elranatamab Induces Durable Responses for Patients with Relapsed or ...
Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 ...
Elranatamab - Single-patient Expanded Access - Multiple Myeloma ...
Elranatamab in relapsed or refractory multiple myeloma: phase 2 ...
Elranatamab (Elrexfio®) Treatment Guide - Myeloma UK
Elranatamab + Daratumumab + Lenalidomide for Multiple Myeloma Clinical ...
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R ...
(PDF) PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB ...
MagnetisMM-6 Data Suggest Safety, Manageability of Elranatamab Combo in ...
Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal ...
Elranatamab – Application in Therapy and Current Clinical Research
Elranatamab efficacy in MagnetisMM-3 compared with real-world control ...
Leveraging quantitative systems pharmacology modeling for elranatamab ...
Initial Safety Results for MagnetisMM-3: Phase 2 Trial of Elranatamab ...
Elranatamab Biosimilar Antibody (Recombinant BCMA-CD3 Bispecific ...
Matching-adjusted indirect comparison of elranatamab versus teclistama ...
(PDF) Elranatamab efficacy in MagnetisMM-3 compared with real-world ...
记住所有FDA生物药 | BCMA×CD3双抗 | Elrexfio® Elranatamab | 多发性骨髓瘤 – 肖恩记药
Experts Guidance for the Treatment of MM: Elranatamab Preceptorships ...
Elranatamab là chất gì? Có công dụng gì? Được tìm mua ở đâu?
Elranatamab receives breakthrough therapy designation for advanced ...
记住所有FDA生物药 | BCMA×CD3双抗 | Elrexfio® Elranatamab | 多发性骨髓瘤 - 知乎
Elranatamab Effective in Relapse after BCMA CAR-T | Int'l Myeloma Fn
Elranatamab in Multiple Myeloma - CancerConnect
Elranatamab (Elrexfio) - NCBI Bookshelf
Elranatamab Plus Iberdomide Shows Early Efficacy in R/R Multiple ...
Elranatamab Myeloma Trials
Fixed-Duration Elranatamab Consolidation Enhances MRD Negativity ...
ASH 2022: Elranatamab in Combination with Daratumumab for Patients (pts ...
Elranatamab treatment in a multiple myeloma patient undergoing renal ...
elranatamab (PF-06863135) / Pfizer
Elranatamab - Upcoming Myeloma Therapy - YouTube
Elranatamab pharmacokinetics A priming dose was not administered during ...
Elranatamab Demonstrates Sustained Efficacy with Reduced Dosing ...
PPT - Elranatamab exhibits a 60.6% ORR and a tolerable safety profile ...
FDA 授予 Elranatamab 用于复发/难治性多发性骨髓瘤的突破性治疗指定 - 知乎
(PDF) P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB ...
Study on Elranatamab for Patients with Multiple Myeloma Continuing from ...
Elranatamab for Black Patients with Relapsed Multiple Myeloma [ASH 2023 ...
Full article: Matching-Adjusted Indirect Comparison of Elranatamab ...
Elranatamab for RRMM: Updates from the MagnetisMM trials
BCMA/CD3 Bispecific Antibodies for Multiple Myeloma (MM) | Biopharma PEG
从16种双抗产品的上市顺序、获批适应症及历年销售看双抗结构的演变_生物器材网
ELREXFIO- elranatamab-bcmm injection, solution
Stage of Development
DailyMed - ELREXFIO- elranatamab-bcmm injection, solution
多发性骨髓瘤(MM)创新疗法！辉瑞BCMA-CD3双特异性抗体elranatamab启动关键2期试验! - 癌症研究专区 - 生物谷
FDA-Granted Priority Review for Pfizer’s Anti-CD3/BCMA Bispecific ...
多发性骨髓瘤，辉瑞双特异性抗体Elranatamab获FDA优先审评 - 知乎
British Journal of Haematology | Wiley Online Library
Overview - by Cancer | Pfizer Oncology Development Website
辉瑞靶向BCMA/CD3双抗Elranatamab获得FDA和EMA备案受理|多发性骨髓瘤|BCMA|恶性肿瘤|淋巴细胞|靶向治疗|CD3 ...
ELREXFIO (elranatamab-bcmm) | International Myeloma Foundation
Phase 1b Trial Initiated for Cemsidomide/Elranatamab in R/R Myeloma ...
辉瑞的Elranatamab获得FDA和EMA申请受理|多发性骨髓瘤|EMA|CD3|细胞|药物|-健康界
Comprehensive Review of Bispecific Antibody Constructs In Multiple ...
An Updated Indirect Comparison of Elranatamab’s Progression-Free Sur ...
Full article: A matching-adjusted indirect comparison of the efficacy ...
全球已上市双抗图鉴Vol.14 | 埃纳妥单抗（Elranatamab） - 知乎
Frontiers | Bispecific antibodies for the treatment of relapsed ...
ELREXFIO (elranatamab-bcmm) Approved By FDA | International Myeloma ...
Pfizer’s Phase 3 Study on Elranatamab: A Potential Game-Changer for ...
Oncology/Hematology articles page [11] | MedPage Today
【Nat Med】BCMA/CD3双抗Elranatamab的注册研究结果-MedSci.cn
MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 ...
CDSCO Panel Denies Pfizer Products India request for local CT waiver to ...
A Novel Two‐Part Mixture Model for the Incidence and Time Course of ...
骨髓瘤复发耐药怎么办？新型皮下注射双抗疗法，有望改写治疗标准
埃纳妥单抗（Elranatamab）的中文说明书_药得
(PDF) S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 ...
辉瑞靶向BCMA/CD3双抗Elranatamab获FDA优先审评
ELREXFIO(elranatamab-bcmm，埃纳妥单抗)中文说明书 | 香港济民药业 - 知乎
CDSCO panel rejects Pfizer Products India Local Clinical Trial Waiver ...
Updates in Multiple Myeloma from ASH 2024 - MMRF
(PDF) Relapsed refractory multiple myeloma with CNS involvement ...
Bispecifics Granted FDA Approval for Myeloma Care
MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer ...
【Blood】多发性骨髓瘤中抗BCMA和GPRC5D双抗的疗效、安全性和耐药机制@MedSci
